Allist(SH:688578) Xin Lang Cai Jing·2025-10-24 02:04Core Viewpoint - Ailis has shown significant stock performance with an 81.24% increase year-to-date and a market capitalization of 48.2 billion yuan as of October 24, 2023 [1] Financial Performance - For the first half of 2025, Ailis reported revenue of 2.374 billion yuan, a year-on-year increase of 50.57%, and a net profit attributable to shareholders of 1.051 billion yuan, up 60.22% [2] - Cumulative cash dividends since Ailis's A-share listing amount to 653 million yuan [3] Shareholder Information - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period, with an average of 34,578 circulating shares per shareholder, down 3.48% [2] - The top ten circulating shareholders include notable entities such as Huaxia SSE STAR 50 ETF and Hong Kong Central Clearing Limited, with varying changes in shareholdings [3] Stock Performance - Ailis's stock price increased by 2.01% to 107.11 yuan per share on October 24, 2023, with a trading volume of 68.7952 million yuan and a turnover rate of 0.14% [1] - The stock has experienced a 2.92% increase over the last five trading days, a 0.36% decrease over the last 20 days, and an 11.83% increase over the last 60 days [1] Company Overview - Ailis, established on March 22, 2004, and listed on December 2, 2020, is based in Shanghai and focuses on the research, production, and sales of innovative pharmaceuticals [1] - The company's revenue composition is predominantly from drug sales (99.93%), with minimal contributions from promotional services [1] Industry Classification - Ailis is classified under the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations [1] - The company is associated with concepts such as biomedicine, anti-cancer drugs, innovative drugs, and mid-cap stocks [1]